Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

OTC OFFICE DIRECTOR MICHAEL WEINTRAUB TO BE RELEASED FROM HOSPITAL early in the week of Sept. 20, following his hospitalization on Sept. 12 for a minor stroke. Weintraub, 54, reportedly suffered the stroke while he was jogging. Although he suffered some partial paralysis after the stroke, as of Sept. 17 Weintraub had regained full function and is reported to be in good condition at Suburban Hospital in Bethesda, Md. Medical Review Staff Director Debra Bowen, MD, will assume responsibility for heading the Office of OTC Drug Evaluation in Weintraub's absence. FDA expects Weintraub to return to the office in the "near future." Weintraub has directed the OTC office since its formation in 1991. Although he was formally appointed director of the office in June ("The Tan Sheet" July 5, In Brief), Weintraub was the defacto steward of the office for nearly two years during which time he was listed as an FDA consultant. Prior to joining the agency, Weintraub was a Mellon Fellow and professor of community medicine, pharmacology, and medicine at the University of Rochester. He received his MD from the University of Pennsylvania. Under Weintraub's direction, the OTC office has moved quickly on several major and controversial OTC drug issues using the new Nonprescription Drugs Advisory Committee and, when appropriate, new drug advisory committees for expert advice. The issues have included alcohol levels in OTC products; a petition from Health Research Group on the efficacy of OTC antidiarrheal ingredients; two major switches -- naproxen and cimetidine; and analgesic labeling covering possible side effects associated with alcohol use.

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts